## Clinical Scenario: Treatment Failure / Relapse This patient has **relapsed visceral leishmaniasis**—clinical and serologic evidence of disease recurrence after initial treatment. Serology remains positive because antibodies persist; clinical relapse (fever, organomegaly, weight loss) is the key diagnostic feature. **Key Point:** Relapse in kala-azar is defined as recurrence of clinical symptoms within 6 months of completing therapy. It indicates either inadequate parasite clearance or drug resistance. ## Management of Relapsed Kala-azar ```mermaid flowchart TD A[Relapsed Kala-azar]:::outcome --> B{Prior treatment?}:::decision B -->|Amphotericin B naive| C[Liposomal Amphotericin B]:::action B -->|Already received Amphotericin B| D[Combination therapy:<br/>Miltefosine + Paromomycin]:::action C --> E[Cure achieved]:::outcome D --> F[Cure achieved]:::outcome B -->|Amphotericin B resistant| G[Miltefosine + Paromomycin<br/>± Liposomal Amphotericin B]:::action ``` ## Treatment Regimens for Relapse | Scenario | First-Line Regimen | Duration | Cure Rate | |----------|-------------------|----------|----------| | **Relapse after Amphotericin B** | Miltefosine + Paromomycin (combination) | Miltefosine: 28 days; Paromomycin: 21 days | 95% | | Relapse after Miltefosine | Liposomal Amphotericin B (second course) | 10–15 days | 90% | | Relapse after Antimonials | Liposomal Amphotericin B | 10–15 days | 95% | | Amphotericin B-resistant relapse | Miltefosine + Paromomycin ± Liposomal Amphotericin B | As above | 85–90% | **High-Yield:** Combination therapy (miltefosine + paromomycin) is the WHO-recommended strategy for relapse after amphotericin B because: - Synergistic activity against drug-resistant parasites - Reduces risk of further resistance - Achieves >95% cure in relapsed cases - Avoids repeated nephrotoxic amphotericin B exposure **Clinical Pearl:** A second course of the same agent (liposomal amphotericin B) is not recommended for relapse because it suggests inadequate response or emerging resistance. Switching to a different drug class or combination is standard practice. **Tip:** Bone marrow aspiration is NOT required for diagnosis of relapse—clinical and serologic evidence suffice. Culture and resistance testing are research tools, not routine practice in endemic settings. [cite:Park 26e Ch 32; WHO Guidelines on Visceral Leishmaniasis (2019)]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.